Biophysical Society Thematic Meeting | Canterbury 2023

Towards a More Perfect Union: Multi-Scale Models of Muscle and Their Experimental Validation

Tuesday Speaker Abstracts

DRUG DESIGN TARGETING MYOSIN BLEBBISTATIN BINDING SITE Andras Malnasi-Csizmadia 1 ; Anna Rauscher 2 ; Mate Gyimesi 1 ; 1 Eötvös University, Dept. of Biochemistry, Budapest, Hungary 2 Motorpharma Ltd, Budapest, Hungary Since the discovery of the first myosin2 specific inhibitor, blebbistatin, several research groups have designed and synthesised thousands of compounds that bind to the blebbistatin binding site. These compounds are derivatives of several different chemical skeletons and have very different biochemical and pharmacological properties. In the meantime, two of these compounds are already in clinical trials for a variety of indications. In my talk I will summarise the historical aspects of these investigations and the recent progress in the field.

38